Business
ValiSeek Clinical Development Update
ValiSeek Clinical Development Update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 0239Z ValiRx PLC 12 December 2017 \n\n \n \n \nVALIRX PLC\n(\"ValiRx\", the \"Company\" or the \"Group\")\n \nVALISEEK CLINICAL DEVELOPMENT UPDATE\n\"Positive Formal Data Release Pertaining to Disease Impact \nfrom VAL401 Phase II Clinical Trial\"\n \nLondon, UK., 12 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited. \nFurther to the release of pharmacokinetic data from the completed Phase II clinical trial in Tbilisi, Georgia (as announced on 28 September 2017), the Company is pleased to now announce the positive formal data release pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival (\"OS\") for patients with non-small cell lung cancer compared to those receiving no treatment.\n \nThis data has been summarised and published in our updated information sheet available at: http://www.valirx.com/in-the-news/valiseek-val401-novel-cancer-therapeutic-updated/\n \nScientific Summary:\nAll data collected during the clinical trial of VAL401 in Tbilisi, Georgia, which completed earlier this year, has now been fully verified and the database has been locked against further modifications. The data analytics team at Ariana Pharma (the company appointed to undertake clinical data analysis of the data gathered during the trial) has received the full database and started its formal analysis. Furthermore, Ariana Pharma is characterising the best responders to VAL401 using their proprietary KEM® (Knowledge Extraction and Management) advanced artificial intelligence technology. \n \nIn addition to the data collected throughout and beyond dosing of the VAL401 treated patients, historical data from the clinics in Tbilisi has been collected in order to benchmark our patients. These patients would have been eligible for the trial, but either declined consent or were treated in the clinic at a time that recruitment was not open in our trial. Although not a placebo group, these patients provide a comparison group to indicate how long our patients may have expec...